Pluristem Announces Scientific and Investment Conferences for April 2013

Pluristem Announces Scientific and Investment Conferences for April 2013

HAIFA, Israel, April 10, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today the Company is scheduled to participate in several
scientific and investment conferences in April 2013. To schedule a meeting
with us upon availability, contact us at

Bizportal Biomed 2013 Conference

On April 10^th in Tel-Aviv, Zami Aberman, Chairman and CEO, will participate
in a panel discussion entitled "Tel-Aviv New York, Gazing to the American
Market and the Exit Dream" at the Bizportal Biomed 2013 Conference.

Regenerative Medicine Investor Day

On April 17^th in New York City, Mr. Aberman will present at the Regenerative
Medicine Investor Day hosted by the Alliance for Regenerative Medicine. The
conference provides institutional, strategic and venture investors a unique
opportunity to gain insight into the top regenerative medicine and advanced
therapies companies.

Israstem, The Annual Israeli Meeting of Translational Research on Stem Cells,
Cell Therapy and Regenerative Medicine in Industry and Academia

On April 22^nd – 23^rd, Dr. Ohad Karnieli, VP Development and Dr. Racheli
Ofir, Intellectual Property & Senior Scientist, will chair a session entitled
"Tools for Research and Development" and give a presentation entitled "A
Harmonized Approach in the Regulation of PLX-PAD" respectively.

BIO-International 2013 Convention

From April 22^nd – 25^th, Mr. Aberman and Dr. William Prather, Sr. VP of
Corporate Development, will participate in the BIO-International 2013
Convention in Chicago, Illinois. This popular biotechnology meeting is well
attended by specialty and large pharmaceutical companies from all over the

19th ISCT Annual Conference

On April 24^th, Dr. Ohad Karnieli, VP Development, will give a presentation
entitled "Challenges and Possible Solutions to Overcome the Gap in Critical
Supply Chain Issues of New and Evolving Cutting Edge Technologies of Cell
Therapy" at the Annual International Society for Cell Therapy Conference in
Auckland, New Zealand.

International Advanced Course on Regenerative Medicine Manufacturing

From April 28^th - May 4^th, Lior Raviv, Team Lead Process Development, will
lecture at the course on Regenerative Medicine Manufacturing in
Tavira-Algarve, Portugal.

Needham Healthcare Conference

From April 30^th - May 1^st, Dr. Prather will attend the 12th Annual Needham
Healthcare Conference held in New York City.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. These forward-looking statements and
their implications are based on the current expectations of the management of
Pluristem only, and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those described in the
forward-looking statements. The following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements; we
may encounter delays or obstacles in launching and/or successfully completing
our clinical trials; our products may not be approved by regulatory agencies,
our technology may not be validated as we progress further and our methods may
not be accepted by the scientific community; we may be unable to retain or
attract key employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our process; our
products may wind up being more expensive than we anticipate; results in the
laboratory may not translate to equally good results in real surgical
settings; results of preclinical studies may not correlate with the results of
human clinical trials; our patents may not be sufficient; our products may
harm recipients; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; loss of market share
and pressure on pricing resulting from competition, which could cause the
actual results or performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Pluristem undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. For a
more detailed description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time with the
Securities and Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         Daya Lettvin
         Investor & Media Relations Director

Pluristem Therapeutics Inc. Logo
Press spacebar to pause and continue. Press esc to stop.